Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
As industry begins to organize around broader self-regulation on drug pricing, PwC Partner Rick Judy expects pharma companies to announce more social contracts with consumers. Industry self-regulation on prices is one of 10 top health issues for 2017 identified by the consulting firm.
Latest From Pricing Debate
Pharmaceutical industry’s message on overall drug spending trends is getting some timely support from the Center for Medicare and Medicaid Services’ annual national health expenditure projections.
As state attorneys general and Department of Justice move against generic manufacturers, plaintiffs’ firms have filed more than 90 antitrust suits on behalf of third party payers.
Pink Sheet has scoured big pharma annual results presentations to gauge the industry's reactions and concerns around the increasingly tough US drug pricing environment and proposed changes to the Affordable Care Act under the new Trump administration.
CMS Administrator-nominee Seema Verma promises stronger agency oversight of Medicaid drug rebate program in response to question from Sen. Grassley during Senate confirmation hearing.
Families of spinal muscular atrophy patients in Turkey are demanding immediate access to Biogen’s Spinraza following its US approval in December. Its public payer is in discussions over possible reimbursement of the high-priced imported drug but the company is said to have shown no pricing flexibility so far.
Amidst a growing chorus of criticism that pharmacy benefit managers are contributing to the problem of high drug costs, PCMA’s Merritt defends the PBM business model and points to its potential for better managing costs in Medicaid.
Lowering the bar on drug approval standards would create a challenging environment for biotech investors, warned Jonathan Leff, a partner at the health care investment firm Deerfield, during the BIO CEO & Investor Conference.
The controversy over Marathon’s pricing of the steroid deflazacort is fueling calls to revisit the US Orphan Drug Act. For Big Pharma companies, the threat should not be ignored. It is time for the industry’s biggest players to take back development of products like deflazacort to protect pricing for more innovative therapies.
Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.